Dicerna Pharmaceuticals Inc (NASDAQ:DRNA): Peter Kolchinsky’s RA Capital Management filed an amended 13D.
You can check out RA Capital Management’s latest holdings and filings here.
Please follow RA Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about RA Capital Management or update its stock holdings.
Follow Peter Kolchinsky's RA Capital Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| RA Capital Management | 0 | 4,462,313 | 0 | 4,462,313 | 4,462,313 | 8.6% |
| Peter Kolchinsky | 0 | 4,462,313 | 0 | 4,462,313 | 4,462,313 | 8.6% |
| RA Capital Healthcare Fund | 0 | 3,908,570 | 0 | 3,908,570 | 3,908,570 | 7.6% |
Follow Peter Kolchinsky's RA Capital Management
Page 1 of 6 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of
1934
(Amendment No. 4)*
Dicerna Pharmaceuticals, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
253031108
(CUSIP Number)
RA Capital Management, LLC
20 Park Plaza, Suite 1200
Boston, MA 02116
Telephone: 617.778.2512
Attn: Peter Kolchinsky
(Name, Address and Telephone Number of Person
Authorized to
Receive Notices and Communications)
January 17, 2018
(Date of Event Which Requires Filing of
this Statement)
If the filing person has previously filed a statement on Schedule 13G
to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. [ ]
Note: Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to
be sent.
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
